CLEVELAND -- Juventas Therapeutics is a local biomedical business spawned from stem cell research at Cleveland Clinic.
Dr. Marc Penn is the lead scientist on a particular molecule that has the ability to heal heart damage. Juventas is taking his research and trying to create a drug with it.
According to the company, their lead product, Stromal-cell Derived Factor 1 (SDF-1), has been shown to protect and repair tissue following organ damage in a broad range of pre-clinical disease models.
The first clinical target will be treatment of patients with advanced heart failure.
Studies have demonstrated that SDF-1 therapy has the potential to improve cardiac function following a heart attack by recruiting the body's own stem cells to the damaged region, the prevention of cardiac cell death and promotion of new blood vessel growth in the heart.
In addition to heart failure, Juventas is developing SDF-1 into a platform therapy with active development programs in peripheral vascular disease and wound healing.